Tuesday, 29 November 2016 08:30 AM
Conferences
SAN DIEGO, CA / ACCESSWIRE / November 29, 2016 / MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company announced today that it will be presenting at the 9th annual LD Micro Main Event on Wednesday, December 7 at 2:00 PM PST / 5:00 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. President and CEO J., David Hansen, of MabVax Therapeutics will be presenting, as well as meeting with investors.
"We look forward to the opportunity to discuss our release in mid-November of interim data on our two HuMab-5B1 antibody phase I programs at the LD Micro Conference. The mid-November release outlined results from our clinical programs evaluating the use of MVT-5873 as a therapeutic antibody, and MVT-2163 as an immuno-PET imaging agent, in patients with locally advanced and metastatic pancreatic cancer," said President and CEO J. David Hansen. He added, "We also expect to share at the conference important progress we have been making in advancing our clinical trial of MVT-5873 into treatment of newly diagnosed patients in combination with a standard of care chemotherapy in previously untreated pancreatic cancer patients."
The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting companies.
The presentation will be webcast. Please use the link below to access the webcast: http://wsw.com/webcast/ldmicro11/mbvx
View MabVax's profile here: http://www.ldmicro.com/profile/MBVX
News Compliments of Accesswire.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines. MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. Additional information is available at www.mabvax.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com/events for more information.
Contact:
Robert Haag, Managing Director
IRTH Communications
[email protected]
1-866-976-4784
SOURCE: MabVax Therapeutics Holdings, Inc. via LD Micro